Human Enhancement Drugs
Volume Two
Herausgeber: McVeigh, Jim; Mulrooney, Kyle J. D.; de Ven, Katinka van
Versandkostenfrei innerhalb Deutschlands
162,99 €
inkl. MwSt.
Versandkostenfrei*
Erscheint vorauss. 22. Januar 2026
Melden Sie sich
hier
hier
für den Produktalarm an, um über die Verfügbarkeit des Produkts informiert zu werden.
81 °P sammeln
Human Enhancement Drugs
Volume Two
Herausgeber: McVeigh, Jim; Mulrooney, Kyle J. D.; de Ven, Katinka van
- Gebundenes Buch
This volume provides fresh insights into sports doping as well as under-researched areas, offering practical and theoretical knowledge for academics, practitioners and policymakers. Key features include a global perspective, contributions from leading experts, and coverage of novel topics.
Andere Kunden interessierten sich auch für
Paul O'MahonyThe Irish War on Drugs116,99 €
George C. Denniston / Pia Grassivaro Gallo / Frederick M. Hodges / Marilyn Fayre Milos / Franco Viviani (eds.)Bodily Integrity and the Politics of Circumcision130,99 €
Richard Muniputu MangandaThe problem of alcoholic beverage consumption among youth29,99 €
Ziya Att Tamhid Ahmed Khan PathanRural-Urban Linkage for Enhancement of Rural Livelihood33,99 €
Geoffrey HuntDrugs and Culture177,99 €
Leon PettiwayWorkin' It: Women Living Through Drugs and Crime76,99 €
Matilda HellmanAddiction and the Brain91,99 €-
-
-
This volume provides fresh insights into sports doping as well as under-researched areas, offering practical and theoretical knowledge for academics, practitioners and policymakers. Key features include a global perspective, contributions from leading experts, and coverage of novel topics.
Produktdetails
- Produktdetails
- Verlag: Taylor & Francis Ltd
- Seitenzahl: 222
- Erscheinungstermin: 22. Januar 2026
- Englisch
- Abmessung: 234mm x 156mm
- ISBN-13: 9781032488370
- ISBN-10: 1032488379
- Artikelnr.: 73775581
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
- Verlag: Taylor & Francis Ltd
- Seitenzahl: 222
- Erscheinungstermin: 22. Januar 2026
- Englisch
- Abmessung: 234mm x 156mm
- ISBN-13: 9781032488370
- ISBN-10: 1032488379
- Artikelnr.: 73775581
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
Katinka van de Ven is Principal Consultant at 360Edge and a Research Manager at Hello Sunday Morning. She is also a Visiting Fellow as part of the Drug Policy Modelling Program (DPMP), Social Policy Research Centre (SPRC), UNSW. Katinka is the Editor-in-Chief of Performance Enhancement & Health and the Founder/Director of the Human Enhancement Drugs Network (HEDN). Kyle J. D. Mulrooney is Senior Lecturer in Criminology and Co-Director of the Centre for Rural Criminology at the University of New England (AU). His research spans diverse areas, including the fields of rural criminology, the sociology of punishment and drug policy, and topics such as crime prevention, policing and enhancement drugs, united by a commitment to understand how social, cultural, and geographic contexts influence the regulation of behaviour and the shaping of justice. Jim McVeigh holds the post of Evidence in Policy and Practice Lead at Change, Grow, Live (a leading United Kingdom drug treatment and support charity). Prior to this he was Professor in Substance Use and Associated Behaviours in the Department of Sociology at Manchester Metropolitan University, where he retains emeritus professor status. Until 2020 he was the Director of the Public Health Institute at Liverpool John Moores University. He has worked within health/public health for nearly 40 years, qualifying as a Registered General Nurse in 1990 and then working with people who inject drugs, before moving into academia. Jim has built an international reputation within the field of substance use, in particular the use of anabolic steroids and associated human enhancement drug use. He has published extensively on the topic and presented at many influential international conferences. He has contributed to UK National Drug Strategies and advised on legislation and health policy and practice.
1 Reflecting on the current human enhancement drugs categorisation and new
directions to consider PART I: Anabolic androgenic steroids and other drugs
associated with the development of lean muscle 2 Anabolic androgenic
steroid use: epidemiology, risk factors and adverse effects 3 On the female
image and performance enhancing drugs experience 4 Thinking in systems to
understand and respond to harmful AAS use 5 The Haarlem experience: an
outpatient clinic for users of anabolic steroids 6 Becoming allies:
combining professional and community-based image and performance enhancing
drug harm reduction efforts 7 "Dropping off the edge of a cliff": a
qualitative exploration of the cessation of anabolic androgenic steroid use
in the United Kingdom PART II: Lifestyle drugs 8 Human enhancement drugs in
rural settings: exploring the role of place and space in anabolic-a
ndrogenic steroid use 9 Contextualising substance use among professionals
in Canada 10 Human enhancement modalities: microdosing psychedelics 11
Enhancing sexual and psychosocial experiences: sexualised drug use among
men who have sex with men 12 "Filling the gaps": understanding oil
injection for cosmetic enhancement 13 Cognitive enhancing drug use in an
age of neoliberalism: issues and implications for future potential
legislation and policy PART III: Sports doping 14 Why anti- doping? 15
Involving stakeholders to develop anti- doping education: bridging the gap
between research and practice 16 Seven failed arguments for the inclusion
of trans women in elite sport 17 Image and performance enhancing drugs and
intersecting populations: recreational Welsh rugby union players and gym
users 18 "Doping cases in football are always involuntary": a critical
review
directions to consider PART I: Anabolic androgenic steroids and other drugs
associated with the development of lean muscle 2 Anabolic androgenic
steroid use: epidemiology, risk factors and adverse effects 3 On the female
image and performance enhancing drugs experience 4 Thinking in systems to
understand and respond to harmful AAS use 5 The Haarlem experience: an
outpatient clinic for users of anabolic steroids 6 Becoming allies:
combining professional and community-based image and performance enhancing
drug harm reduction efforts 7 "Dropping off the edge of a cliff": a
qualitative exploration of the cessation of anabolic androgenic steroid use
in the United Kingdom PART II: Lifestyle drugs 8 Human enhancement drugs in
rural settings: exploring the role of place and space in anabolic-a
ndrogenic steroid use 9 Contextualising substance use among professionals
in Canada 10 Human enhancement modalities: microdosing psychedelics 11
Enhancing sexual and psychosocial experiences: sexualised drug use among
men who have sex with men 12 "Filling the gaps": understanding oil
injection for cosmetic enhancement 13 Cognitive enhancing drug use in an
age of neoliberalism: issues and implications for future potential
legislation and policy PART III: Sports doping 14 Why anti- doping? 15
Involving stakeholders to develop anti- doping education: bridging the gap
between research and practice 16 Seven failed arguments for the inclusion
of trans women in elite sport 17 Image and performance enhancing drugs and
intersecting populations: recreational Welsh rugby union players and gym
users 18 "Doping cases in football are always involuntary": a critical
review
1 Reflecting on the current human enhancement drugs categorisation and new
directions to consider PART I: Anabolic androgenic steroids and other drugs
associated with the development of lean muscle 2 Anabolic androgenic
steroid use: epidemiology, risk factors and adverse effects 3 On the female
image and performance enhancing drugs experience 4 Thinking in systems to
understand and respond to harmful AAS use 5 The Haarlem experience: an
outpatient clinic for users of anabolic steroids 6 Becoming allies:
combining professional and community-based image and performance enhancing
drug harm reduction efforts 7 "Dropping off the edge of a cliff": a
qualitative exploration of the cessation of anabolic androgenic steroid use
in the United Kingdom PART II: Lifestyle drugs 8 Human enhancement drugs in
rural settings: exploring the role of place and space in anabolic-a
ndrogenic steroid use 9 Contextualising substance use among professionals
in Canada 10 Human enhancement modalities: microdosing psychedelics 11
Enhancing sexual and psychosocial experiences: sexualised drug use among
men who have sex with men 12 "Filling the gaps": understanding oil
injection for cosmetic enhancement 13 Cognitive enhancing drug use in an
age of neoliberalism: issues and implications for future potential
legislation and policy PART III: Sports doping 14 Why anti- doping? 15
Involving stakeholders to develop anti- doping education: bridging the gap
between research and practice 16 Seven failed arguments for the inclusion
of trans women in elite sport 17 Image and performance enhancing drugs and
intersecting populations: recreational Welsh rugby union players and gym
users 18 "Doping cases in football are always involuntary": a critical
review
directions to consider PART I: Anabolic androgenic steroids and other drugs
associated with the development of lean muscle 2 Anabolic androgenic
steroid use: epidemiology, risk factors and adverse effects 3 On the female
image and performance enhancing drugs experience 4 Thinking in systems to
understand and respond to harmful AAS use 5 The Haarlem experience: an
outpatient clinic for users of anabolic steroids 6 Becoming allies:
combining professional and community-based image and performance enhancing
drug harm reduction efforts 7 "Dropping off the edge of a cliff": a
qualitative exploration of the cessation of anabolic androgenic steroid use
in the United Kingdom PART II: Lifestyle drugs 8 Human enhancement drugs in
rural settings: exploring the role of place and space in anabolic-a
ndrogenic steroid use 9 Contextualising substance use among professionals
in Canada 10 Human enhancement modalities: microdosing psychedelics 11
Enhancing sexual and psychosocial experiences: sexualised drug use among
men who have sex with men 12 "Filling the gaps": understanding oil
injection for cosmetic enhancement 13 Cognitive enhancing drug use in an
age of neoliberalism: issues and implications for future potential
legislation and policy PART III: Sports doping 14 Why anti- doping? 15
Involving stakeholders to develop anti- doping education: bridging the gap
between research and practice 16 Seven failed arguments for the inclusion
of trans women in elite sport 17 Image and performance enhancing drugs and
intersecting populations: recreational Welsh rugby union players and gym
users 18 "Doping cases in football are always involuntary": a critical
review







